A discussion regarding the complexities and potential solutions in implementing therapeutic drug monitoring for elexacaftor/tezacaftor/ivacaftor (ETI) therapy in patients with cystic fibrosis. The topic specifically addresses challenges related to managing concurrent infections and drug interactions.